Table 2 Association between tumor site, nodal status, group stage and BP dose

Combined BP (n = 136)

SITE (OC, OPhx, NPhx, Larynx, UNP, HPhx)

N status (N0 – N3)

Group stage (I-III vs. IV)

Mean dose

0.005

0.0002

0.037

Max dose

0.0002

0.002

0.17

V50cc

0.012

< .0001

0.049

V60cc

0.0003

< .0001

0.08

V70cc

0.002

< .0001

0.33

V75cc

0.19

0.08

0.039

D5

0.0005

0.0001

0.12

D10

< .0001

< .0001

0.026

D15

0.0006

< .0001

0.06

D20

0.003

< .0001

0.022

D25

0.22

< .0001

0.10

D30

0.002

< .0001

0.07

Ipsilateral BP (n = 68)

SITE

N status (N0 – N3)

Group stage (I-III vs. IV)

Mean dose

< .0001

< .0001

0.06

Max dose

0.038

0.021

0.20

V50cc

0.004

0.001

0.10

V60cc

0.019

< .0001

0.010

V70cc

0.53

< .0001

0.06

V75cc

0.53

0.001

0.28

D5

0.004

0.0004

0.11

D10

0.003

< .0001

0.007

D15

0.001

0.0006

0.08

D20

0.001

< .0001

0.021

D25

0.013

0.0003

0.14

D30

0.0004

0.0004

0.06

Contralateral BP (n = 68)

SITE (OC, OPhx, NPhx, Larynx, UNP, HPhx)

N status (N0 – N3)

Group stage (I-III vs. IV)

Mean dose

< .0001

0.004

0.045

Max dose

< .0001

0.10

0.29

V50cc

0.003

0.006

0.041

V60cc

< .0001

0.021

0.44

V70cc

0.15

0.20

0.66

V75cc

0.15

0.86

0.52

D5

< .0001

0.042

0.21

D10

< .0001

0.030

0.14

D15

0.0001

0.004

0.09

D20

< .0001

0.009

0.11

D25

< .0001

0.018

0.19

D30

< .0001

0.006

0.13